Ascelia Pharma – Presentation of Full-Year report 2023

Name: Ascelia Pharma – Presentation of Full-Year report 2023
Uploaded: 2024-01-12T08:28:47.996Z
Description: The topic for this event is the Q4 and Full-Year report and major events during the last quarter in 2023. In Q4, Ascelia Pharma announced a re-start of the Imaging Reading Phase and re-confirmed Phase 3 SPARKLE results by May 2024. Ascelia Pharma will update the investor community on the roll-out strategy for Orviglance to the market.

ACE09.02.2024, 11.30

HC Andersen Capital

Discuss

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma on 9 February at 11:30 AM.

The topic for this event is the Q4 and Full-Year report and major events during the last quarter in 2023. In Q4, Ascelia Pharma announced a re-start of the Imaging Reading Phase and re-confirmed Phase 3 SPARKLE results by May 2024. Ascelia Pharma will update the investor community on the roll-out strategy for Orviglance to the market.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 12/1/2024 09.03 AM.

Recent videos